BioSpace News Archive

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it will report financial results for the fourth quarter and full year 2023 on Monday, February 26, 2024, after market close.

PHAXIAM Therapeutics announced it has given formal notice to the Nasdaq Stock Market of the Company’s intention to voluntary delist its American Depositary Shares representing its ordinary shares, which delisting is anticipated to be effective prior to the opening of trading on March 11, 2024, at which time the ADSs will no longer trade on The Nasdaq Capital Market.

CymaBay Therapeutics, Inc. announced the grant of inducement awards to three employees on February 16, 2024 in connection with the employees’ commencement of employment at CymaBay.

Annexon, Inc. announced that it has granted inducement to a new non-executive employee under the terms of the 2022 Employment Inducement Award Plan.

Arvinas, Inc. announced that after more than a decade with the company, Sean Cassidy, C.P.A, Chief Financial Officer and Treasurer, will be leaving the company to pursue a new opportunity, effective February 29, 2024.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme” or the “Company”) today reported its financial and operating results for the fourth quarter and full year ended December 31, 2023 and provided an update on its recent corporate activities and outlook.

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced that it will host a live webcast at 5 a.m. PT / 8 a.m. ET on Tuesday, February 27, 2024 to report its fourth quarter and full year 2023 financial results and provide a corporate update.

Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”)

On February 19, 2024, the Journal of American Medical Association•Neurology published online the key findings of a phase III clinical study investigating Sanbexin® sublingual tablets for the treatment of acute ischemic stroke.